

Anti-MyD88 Picoband Antibody

Catalog # ABO11846

Product Information

Application	WB, IHC-P
Primary Accession	P35354
Host	Rabbit
Reactivity	Human, Mouse, Rat
Clonality	Polyclonal
Format	Lyophilized
Description	Rabbit IgG polyclonal antibody for Myeloid differentiation primary response protein MyD88(MYD88) detection. Tested with WB, IHC-P in Human;Mouse;Rat.
Reconstitution	Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

Additional Information

Gene ID	5743
Other Names	Prostaglandin G/H synthase 2, 1.14.99.1, Cyclooxygenase-2, COX-2, PHS II, Prostaglandin H2 synthase 2, PGH synthase 2, PGHS-2, Prostaglandin-endoperoxide synthase 2, PTGS2, COX2
Calculated MW	68996
Application Details	Immunohistochemistry(Paraffin-embedded Section), 0.5-1 µg/ml, Human, Mouse, Rat, By Heat Western blot, 0.1-0.5 µg/ml, Human, Rat
Subcellular Localization	Microsome membrane; Peripheral membrane protein. Endoplasmic reticulum membrane; Peripheral membrane protein.
Tissue Specificity	Ubiquitous.
Source	Eukaryota
Protein Name	Myeloid differentiation primary response protein MyD88
Contents	Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.
Immunogen	E.coli-derived human MyD88 recombinant protein (Position: A44-F264). Human MyD88 shares 84% and 83% amino acid (aa) sequences identity with mouse and rat MyD88, respectively.
Purification	Immunogen affinity purified.

Cross Reactivity	No cross reactivity with other proteins
Storage	At -20 °C for one year. After r ° Constitution, at 4 °C for one month. It ° Can also be aliquotted and stored frozen at -20 °C for a longer time.Avoid repeated freezing and thawing.
Sequence Similarities	Contains 1 death domain.

Protein Information

Name	PTGS2 (HGNC:9605)
Function	Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response (PubMed:11939906, PubMed:16373578, PubMed:19540099, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes (PubMed:16373578, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S- stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed:16373578, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins (PubMed:11939906, PubMed:19540099). In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophospholipids to prostanoid lysophospholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids (PubMed:27642067). Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response (PubMed:22942274). Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols (PubMed:11034610, PubMed:11192938, PubMed:9048568, PubMed:9261177). Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation (PubMed:12391014). Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) (PubMed:12391014). As a component of the biosynthetic pathway of E- series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 (PubMed:21206090). In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R- HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection (PubMed:26236990). In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11- diHETE) (PubMed:22068350, PubMed:26282205). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)- HODE

((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity).

Cellular Location

Microsome membrane; Peripheral membrane protein. Endoplasmic reticulum membrane; Peripheral membrane protein. Nucleus inner membrane; Peripheral membrane protein. Nucleus outer membrane; Peripheral membrane protein. Note=Detected on the luminal side of the endoplasmic reticulum and nuclear envelope


Background

MYD88(MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE 88), is a protein that, in humans, is encoded by the MYD88 gene. MyD88 is a key downstream adapter for most Toll-like receptors (TLRs) and interleukin-1 receptors (IL1Rs). And it is mapped on 3p22.2. MYD88 encodes a cytosolic adapter protein that plays a central role in the innate and adaptive immune response. This protein functions as an essential signal transducer in the interleukin-1 and Toll-like receptor signaling pathways. Overexpression of MYD88 caused an increase in the level of transcription from the interleukin-8 promoter. The C-terminal domain of MYD88 has significant sequence similarity to the cytoplasmic domain of IL1RAP. Inhibiting the IL1R-MYD88 pathway in vivo could block the damage from acute inflammation that occurs in response to sterile cell death, and do so in a way that might not compromise tissue repair or host defense against pathogens.

Images




Anti-MyD88 Picoband antibody, ABO11846-1.jpgAll lanes:
Anti MYD88 (ABO11846) at 0.5ug/mlWB: Recombinant
Human MYD88 Protein 0.5ngPredicted bind size:
49KDObserved bind size: 49KD




Anti-MyD88 Picoband antibody, ABO11846-2.jpgAll lanes:
Anti MYD88 (ABO11846) at 0.5ug/mlLane 1: Rat Cardiac
Muscle Tissue Lysate at 50ugLane 2: HELA Whole Cell
Lysate at 40ugLane 3: MCF Whole Cell Lysate at 40ugLane 4: HEPG2 Whole Cell Lysate at 40ugLane 5: JURKAT Whole
Cell Lysate at 40ugLane 6: RAJI Whole Cell Lysate at
40ugPredicted bind size: 33KD Observed bind size: 33KD


Anti-MyD88 Picoband antibody, ABO11846-3.JPGIHC(P):
Rat Lung Tissue



Anti-MyD88 Picoband antibody, ABO11846-4.JPGIHC(P):
Human Intestinal Cancer Tissue



Anti-MyD88 Picoband antibody, ABO11846-5.JPGIHC(P):
Mouse Spleen Tissue



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.